Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are the two major causative agents of hand, foot and mouth disease (HFMD), for which there are currently no licenced treatments. Here, the acquisition of resistance towards two novel capsid-binding compounds, NLD and ALD, was studied and compared to the analogous compound GPP3. During serial passage, EV71 rapidly became resistant to each compound and mutations at residues I113 and V123 in VP1 were identified. A mutation at residue 113 was also identified in CVA16 after passage with GPP3. The mutations were associated with reduced thermostability and were rapidly lost in the absence of inhibitors. In silico modelling suggested that the mutations prevented the compounds from binding the VP1 pocket in the capsid. Although both viruses developed resistance to these potent pocket-binding compounds, the acquired mutations were associated with large fitness costs and reverted to WT phenotype and sequence rapidly in the absence of inhibitors. The most effective inhibitor, NLD, had a very large selectivity index, showing interesting pharmacological properties as a novel anti-EV71 agent.

Original publication

DOI

10.1016/j.antiviral.2015.10.006

Type

Journal article

Journal

Antiviral Res

Publication Date

12/2015

Volume

124

Pages

77 - 82

Keywords

Capsid binding, Drug resistance, Fitness, Hand foot and mouth disease, VP1 pocket, Animals, Antiviral Agents, Capsid, Capsid Proteins, Cell Line, Crystallography, X-Ray, Drug Resistance, Viral, Enterovirus, Enterovirus A, Human, Hand, Foot and Mouth Disease, Humans, Models, Molecular, Mutation, Protein Conformation, Vero Cells